{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T05:53:08Z","timestamp":1725083588773},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jgo.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T08:43:48Z","timestamp":1547801028000},"page":"518-520","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials"],"prefix":"10.1016","volume":"10","author":[{"given":"Somedeb","family":"Ball","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myo H.","family":"Zaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyaw Z.","family":"Thein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2019.01.008_bb0005","article-title":"PARP inhibitors in older patients with ovarian and breast cancer: Young international society of geriatric oncology review paper","author":"Liposits","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2019.01.008_bb0010","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2019.01.008_bb0015","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2019.01.008_bb0020","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2019.01.008_bb0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jgo.2019.01.008_bb0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/10428194.2010.551155","article-title":"Abnormalities of DNA repair mechanisms in common hematological malignancies","volume":"52","author":"Economopoulou","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2019.01.008_bb0035","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jgo.2019.01.008_bb0040","article-title":"BRCA mutations: is everything said?","author":"L\u00f3pez-Urrutia","year":"2018","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818304053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406818304053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T12:27:27Z","timestamp":1565785647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406818304053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S1879406818304053"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2019.01.008","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}